---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-24-000007"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T22:44:21.503574+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q4 revenue $230M (+27% YoY); reiterates 2024 guidance; $750M buyback

## Summary
- Q4 revenue $230M (+27% YoY); GAAP EPS $0.65, non-GAAP EPS $0.82; FY23 revenue $829M (+26%).
- 2024 guidance: revenue $915-985M (10-19% growth), non-GAAP EPS $3.55-3.90 (28-41% growth).
- New $750M share repurchase program announced, reflecting confidence in growth.
- Partner milestones: argenx VYVGART Hytrulo FDA priority review for CIDP (PDUFA June 21); $23M milestone.
- Roche's Tecentriq SC received EU approval; Takeda's HYQVIA approved for CIDP in US and EU.

## SEC filing metadata
- accession: 0001159036-24-000007
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/halo-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-24-000007
- JSON: https://secwatch.observer/filing/0001159036-24-000007.json
- Plain text: https://secwatch.observer/filing/0001159036-24-000007.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported 2024 results: revenue $915-985 Million, EPS $3.55-3.90. Guidance reaffirmed.
  - Period: 2024
  - Revenue: $915-985 Million
  - EPS: $3.55-3.90
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported Full Year 2023 results: revenue $829.3 million, EPS $2.10.
  - Period: Full Year 2023
  - Revenue: $829.3 million
  - EPS: $2.10
  - Result: reported results
  source text: Full Year 2023 Revenue Increased 26% YOY to $829 million; GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.77
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported Fourth Quarter 2023 results: revenue $230.0 million, EPS $0.65.
  - Period: Fourth Quarter 2023
  - Revenue: $230.0 million
  - EPS: $0.65
  - Result: reported results
  source text: Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.82
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.